Chinese and foreign studies reveal the cellular immune fightback in patients with MIDDLES

Researchers from China, the United States and Saudi Arabia said in a new issue of the U.S.
on Aug. 4 that by studying blood samples from patients with Middle East Respiratory Syndrome, they have revealed for the first time the mechanisms of the body's cellular immune "fightback" against the deadly disease. This provides the basis for evaluating the patient's prognostise and developing the relevant vaccine.
the study was carried out in collaboration with Professor Zhao Jinxuan of guangzhou Medical University's National Key Laboratory for Respiratory Diseases, Professor Stanley Perlman of the University of Iowa, USA, and Dr. Abil Ashukari of the King Faisal Specialist Hospital and Research Center in Saudi Arabia.
Zhao Jinxuan told Xinhua that previous research has focused on human antibodies, but some people infected with MIDDLES have short antibody responses and low levels, so they turned to T cells that also play an important role in the body's immune system.
Using blood samples from 21 Saudi patients, they found that THES coronavirus infects the body and induces T-cell responses, which are detected in most patients with low antibody levels, the first time in the world.
further studies have shown that antibody and T-cell response levels in PATIENTs with MES are associated with the severity of the disease.
study identified multiple T-cell mesothets that could serve as targets for human vaccine design. Doctors can use these T-cell tables to effectively monitor the effectiveness of vaccine-induced T-cell responses in humans.
first detected in Saudi Arabia in 2012, and patients with respiratory problems can cause death in severe cases. Currently, scientists are developing a variety of MIDDLES vaccines, but no effective vaccine has been approved for use in humans. (Source: Xinhua News Agency, Lin Xiaochun)